Kao Y-S
Department of radiation oncology, China medical university hospital, Taichung, Taiwan.
Cancer Radiother. 2023 Apr;27(2):96-102. doi: 10.1016/j.canrad.2022.07.014. Epub 2022 Aug 23.
The neoadjuvant radiotherapy is now standard treatment in soft tissue sarcoma. Using ultra-hypofractionation radiotherapy shorten the treatment time. In the era of COVID pandemic, using less fraction to treat patient is an urgent need. Thus, we aim to use meta-analysis to investigate the clinical efficacy of preoperative stereotactic body radiotherapy.
PRISMA guideline was used in this study. PubMed, Cochrane and Embase were used. We include only prospective study. The main endpoint was set as wound complication rate. Other endpoints include R0 resection rate, overall survival, local control, and distant metastasis free survival.
Seven studies were included. The pooled wound complication rate is 0.30 (95% CI=0.26-0.35). The pooled R0 resection rate is 0.87(95%CI: 0.74-0.94). The pooled 2-year overall survival is 0.86 (95%CI: 0.72-0.94). The pooled 2-year local control rate is 0.96(95%CI: 0.89-0.99). The pooled 2-year distant metastasis free survival is 0.60 (95%CI=0.50-0.70).
Neoadjuvant ultra-hypofractionation radiotherapy in soft tissue sarcoma is a feasible and well tolerable treatment.
新辅助放疗目前是软组织肉瘤的标准治疗方法。采用超分割放疗可缩短治疗时间。在新冠疫情时代，减少放疗次数来治疗患者成为迫切需求。因此，我们旨在通过荟萃分析来研究术前立体定向体部放疗的临床疗效。
本研究采用PRISMA指南。检索了PubMed、Cochrane和Embase数据库。仅纳入前瞻性研究。主要终点设定为伤口并发症发生率。其他终点包括R0切除率、总生存率、局部控制率和无远处转移生存率。
纳入了7项研究。汇总的伤口并发症发生率为0.30（95%CI = 0.26 - 0.35）。汇总的R0切除率为0.87（95%CI：0.74 - 0.94）。汇总的2年总生存率为0.86（95%CI：0.72 - 0.94）。汇总的2年局部控制率为0.96（95%CI：0.89 - 0.99）。汇总的2年无远处转移生存率为0.60（95%CI = 0.50 - 0.70）。
软组织肉瘤的新辅助超分割放疗是一种可行且耐受性良好的治疗方法。
